{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:51:01Z","timestamp":1761821461716,"version":"build-2065373602"},"reference-count":95,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T00:00:00Z","timestamp":1692144000000},"content-version":"vor","delay-in-days":592,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s13311-021-01161-z","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T15:53:51Z","timestamp":1638460431000},"page":"55-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Lewy Body Dementias: Controversies and Drug Development"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6143-9867","authenticated-orcid":false,"given":"Shannon Y.","family":"Chiu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawn","family":"Bowers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa J.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-021-01161-z_bib1","unstructured":"LBDA. Diagnosing and Managing Lewy Body Dementia: A Comprehensive Guide for Healthcare Professionals. wwwlbdaorg2017."},{"issue":"2","key":"10.1007\/s13311-021-01161-z_bib2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/alzrt251","article-title":"Lewy body dementia: the impact on patients and caregivers","volume":"6","author":"Zweig","year":"2014","journal-title":"Alzheimers Res Ther."},{"issue":"10004","key":"10.1007\/s13311-021-01161-z_bib3","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(15)00462-6","article-title":"Lewy body dementias","volume":"386","author":"Walker","year":"2015","journal-title":"Lancet."},{"key":"10.1007\/s13311-021-01161-z_bib4","doi-asserted-by":"crossref","unstructured":"Espinosa R, Davis M, Johnson S, Cline S, Weintraub D. Direct Medical Costs of Dementia With Lewy Bodies by Disease Complexity. J Am Med Dir Assoc. 2020;21(11):1696\u2013704 e5.","DOI":"10.1016\/j.jamda.2020.06.006"},{"issue":"23","key":"10.1007\/s13311-021-01161-z_bib5","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1212\/WNL.0000000000004717","article-title":"Alzheimer's Disease-Related Dementias Summit 2016: National research priorities","volume":"89","author":"Corriveau","year":"2017","journal-title":"Neurology."},{"key":"10.1007\/s13311-021-01161-z_bib6","unstructured":"Schneider J JS, Gladman JT, Corriveau RA., editor ADRD Summit 2019: Report to the National Advisory Neurological Disorders and Stroke Council.\u00a02019: National Institute of Neurological Disorders and Strokes."},{"issue":"1","key":"10.1007\/s13311-021-01161-z_bib7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrneurol.2012.242","article-title":"100 years of Lewy pathology","volume":"9","author":"Goedert","year":"2013","journal-title":"Nat Rev Neurol."},{"issue":"Pt A","key":"10.1007\/s13311-021-01161-z_bib8","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.expneurol.2017.10.017","article-title":"Critical appraisal of pathology transmission in the alpha-synuclein fibril model of Lewy body disorders","volume":"299","author":"Nouraei","year":"2018","journal-title":"Exp Neurol."},{"issue":"2","key":"10.1007\/s13311-021-01161-z_bib9","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00401-010-0711-0","article-title":"The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia","volume":"120","author":"Schulz-Schaeffer","year":"2010","journal-title":"Acta Neuropathol."},{"issue":"1","key":"10.1007\/s13311-021-01161-z_bib10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.neuron.2011.08.033","article-title":"Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death","volume":"72","author":"Volpicelli-Daley","year":"2011","journal-title":"Neuron."},{"key":"10.1007\/s13311-021-01161-z_bib11","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3389\/fnins.2016.00408","article-title":"Alpha-Synuclein Oligomers-Neurotoxic Molecules in Parkinson's Disease and Other Lewy Body Disorders","volume":"10","author":"Ingelsson","year":"2016","journal-title":"Front Neurosci."},{"issue":"3","key":"10.1007\/s13311-021-01161-z_bib12","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1212\/WNL.0000000000008822","article-title":"Author response: Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases","volume":"94","author":"Espay","year":"2020","journal-title":"Neurology."},{"issue":"5","key":"10.1007\/s13311-021-01161-z_bib13","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/jnc.14808","article-title":"alpha-synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities","volume":"150","author":"Alam","year":"2019","journal-title":"J Neurochem."},{"issue":"10","key":"10.1007\/s13311-021-01161-z_bib14","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1212\/01.WNL.0000065889.42856.F2","article-title":"Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies","volume":"60","author":"Merdes","year":"2003","journal-title":"Neurology."},{"issue":"3","key":"10.1007\/s13311-021-01161-z_bib15","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/01.jnen.0000205145.54457.ea","article-title":"Biochemical staging of synucleinopathy and amyloid deposition in dementia with Lewy bodies","volume":"65","author":"Deramecourt","year":"2006","journal-title":"J Neuropathol Exp Neurol."},{"issue":"5","key":"10.1007\/s13311-021-01161-z_bib16","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/nan.12294","article-title":"Cortical Lewy bodies and Abeta burden are associated with prevalence and timing of dementia in Lewy body diseases","volume":"42","author":"Ruffmann","year":"2016","journal-title":"Neuropathol Appl Neurobiol."},{"issue":"5","key":"10.1007\/s13311-021-01161-z_bib17","first-page":"185","article-title":"Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree\u2013a new disease?","volume":"3","author":"Kosaka","year":"1984","journal-title":"Clin Neuropathol."},{"issue":"8","key":"10.1007\/s13311-021-01161-z_bib18","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2183\/pjab.90.301","article-title":"Lewy body disease and dementia with Lewy bodies","volume":"90","author":"Kosaka","year":"2014","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci."},{"issue":"16","key":"10.1007\/s13311-021-01161-z_bib19","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1002\/mds.21844","article-title":"Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force","volume":"22","author":"Dubois","year":"2007","journal-title":"Mov Disord."},{"issue":"1","key":"10.1007\/s13311-021-01161-z_bib20","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology."},{"key":"10.1007\/s13311-021-01161-z_bib21","doi-asserted-by":"crossref","unstructured":"Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord. 2007;22(12):1689\u2013707; quiz 837.","DOI":"10.1002\/mds.21507"},{"issue":"12","key":"10.1007\/s13311-021-01161-z_bib22","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson's disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov Disord."},{"issue":"1","key":"10.1007\/s13311-021-01161-z_bib23","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1212\/CON.0000000000000685","article-title":"Lewy Body Dementias","volume":"25","author":"Armstrong","year":"2019","journal-title":"Continuum (Minneap Minn)."},{"issue":"11","key":"10.1007\/s13311-021-01161-z_bib24","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/mds.26796","article-title":"Abolishing the 1-year rule: How much evidence will be enough?","volume":"31","author":"Postuma","year":"2016","journal-title":"Mov Disord."},{"issue":"11","key":"10.1007\/s13311-021-01161-z_bib25","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1002\/mds.26721","article-title":"Arguing against the proposed definition changes of PD","volume":"31","author":"Boeve","year":"2016","journal-title":"Mov Disord."},{"issue":"10","key":"10.1007\/s13311-021-01161-z_bib26","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S1474-4422(10)70194-0","article-title":"Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial","volume":"9","author":"Emre","year":"2010","journal-title":"Lancet Neurol."},{"issue":"8","key":"10.1007\/s13311-021-01161-z_bib27","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1176\/appi.ajp.2015.14121582","article-title":"Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis","volume":"172","author":"Stinton","year":"2015","journal-title":"Am J Psychiatry."},{"issue":"20","key":"10.1007\/s13311-021-01161-z_bib28","doi-asserted-by":"crossref","first-page":"e2076","DOI":"10.1212\/WNL.0000000000009434","article-title":"Cognitive decline profiles differ in Parkinson disease dementia and dementia with Lewy bodies","volume":"94","author":"Smirnov","year":"2020","journal-title":"Neurology."},{"issue":"12","key":"10.1007\/s13311-021-01161-z_bib29","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","article-title":"Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium","volume":"65","author":"McKeith","year":"2005","journal-title":"Neurology."},{"issue":"1","key":"10.1007\/s13311-021-01161-z_bib30","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13195-020-00703-5","article-title":"Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials","volume":"12","author":"Goldman","year":"2020","journal-title":"Alzheimers Res Ther."},{"issue":"10","key":"10.1007\/s13311-021-01161-z_bib31","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/j.1742-1241.2008.01869.x","article-title":"Diagnosis and management of Parkinson's disease dementia","volume":"62","author":"Poewe","year":"2008","journal-title":"Int J Clin Pract."},{"key":"10.1007\/s13311-021-01161-z_bib32","unstructured":"American Psychiatric Association., American Psychiatric Association. Task Force on DSM-IV. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. 4th ed. Washington, DC: American Psychiatric Association; 2000. xxxvii, 943 p."},{"issue":"4","key":"10.1007\/s13311-021-01161-z_bib33","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1590\/S1980-57642009DN20400005","article-title":"Dementia with Parkinson disease: Clinical diagnosis, neuropsychological aspects and treatment","volume":"2","author":"Otero","year":"2008","journal-title":"Dement Neuropsychol."},{"issue":"8","key":"10.1007\/s13311-021-01161-z_bib34","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.parkreldis.2011.05.017","article-title":"Dementia associated with Parkinson's disease: applying the Movement Disorder Society Task Force criteria","volume":"17","author":"Martinez-Martin","year":"2011","journal-title":"Parkinsonism Relat Disord."},{"issue":"3","key":"10.1007\/s13311-021-01161-z_bib35","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/mds.24893","article-title":"Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines","volume":"27","author":"Litvan","year":"2012","journal-title":"Mov Disord."},{"issue":"3","key":"10.1007\/s13311-021-01161-z_bib36","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/mds.27617","article-title":"Risk of Parkinson's disease dementia related to level I MDS PD-MCI","volume":"34","author":"Hoogland","year":"2019","journal-title":"Mov Disord."},{"issue":"7","key":"10.1007\/s13311-021-01161-z_bib37","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/mds.27002","article-title":"Mild cognitive impairment as a risk factor for Parkinson's disease dementia","volume":"32","author":"Hoogland","year":"2017","journal-title":"Mov Disord."},{"issue":"14","key":"10.1007\/s13311-021-01161-z_bib38","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/mds.25655","article-title":"Defining optimal cutoff scores for cognitive impairment using Movement Disorder Society Task Force criteria for mild cognitive impairment in Parkinson's disease","volume":"28","author":"Goldman","year":"2013","journal-title":"Mov Disord."},{"issue":"3","key":"10.1007\/s13311-021-01161-z_bib39","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/mds.26084","article-title":"Diagnosing PD-MCI by MDS Task Force criteria: how many and which neuropsychological tests?","volume":"30","author":"Goldman","year":"2015","journal-title":"Mov Disord."},{"issue":"1","key":"10.1007\/s13311-021-01161-z_bib40","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.parkreldis.2014.10.020","article-title":"Assessing the utility of the Movement Disorder Society Task Force Level 1 diagnostic criteria for mild cognitive impairment in Parkinson's disease","volume":"21","author":"Szeto","year":"2015","journal-title":"Parkinsonism Relat Disord."},{"issue":"17","key":"10.1007\/s13311-021-01161-z_bib41","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1212\/WNL.0000000000009323","article-title":"Research criteria for the diagnosis of prodromal dementia with Lewy bodies","volume":"94","author":"McKeith","year":"2020","journal-title":"Neurology."},{"issue":"9","key":"10.1007\/s13311-021-01161-z_bib42","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nrn3549","article-title":"Parkinson's disease dementia: convergence of alpha-synuclein, tau and amyloid-beta pathologies","volume":"14","author":"Irwin","year":"2013","journal-title":"Nat Rev Neurosci."},{"key":"10.1007\/s13311-021-01161-z_bib43","unstructured":"Irwin DJ, Hurtig HI. The Contribution of Tau, Amyloid-Beta and Alpha-Synuclein Pathology to Dementia in Lewy Body Disorders. J Alzheimers Dis Parkinsonism. 2018;8(4)."},{"issue":"Pt 8","key":"10.1007\/s13311-021-01161-z_bib44","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1093\/brain\/aws173","article-title":"Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies","volume":"135","author":"Graff-Radford","year":"2012","journal-title":"Brain."},{"issue":"214","key":"10.1007\/s13311-021-01161-z_bib45","first-page":"e7","article-title":"Genome-wide analysis of genetic correlation in dementia with Lewy bodies","volume":"38","author":"Guerreiro","year":"2016","journal-title":"Parkinson's and Alzheimer's diseases. Neurobiol Aging."},{"issue":"1","key":"10.1007\/s13311-021-01161-z_bib46","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1474-4422(16)30291-5","article-title":"Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis","volume":"16","author":"Irwin","year":"2017","journal-title":"Lancet Neurol."},{"issue":"19","key":"10.1007\/s13311-021-01161-z_bib47","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1212\/WNL.0b013e3182735e9a","article-title":"GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology","volume":"79","author":"Tsuang","year":"2012","journal-title":"Neurology."},{"issue":"3","key":"10.1007\/s13311-021-01161-z_bib48","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1212\/WNL.0000000000008818","article-title":"beta-Amyloid PET and neuropathology in dementia with Lewy bodies","volume":"94","author":"Kantarci","year":"2020","journal-title":"Neurology."},{"issue":"3","key":"10.1007\/s13311-021-01161-z_bib49","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/ana.25824","article-title":"Alpha-Synuclein Oligomers and Neurofilament Light Chain in Spinal Fluid Differentiate Multiple System Atrophy from Lewy Body Synucleinopathies","volume":"88","author":"Singer","year":"2020","journal-title":"Ann Neurol."},{"issue":"2","key":"10.1007\/s13311-021-01161-z_bib50","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jamaneurol.2016.4547","article-title":"Development of a Biochemical Diagnosis of Parkinson Disease by Detection of alpha-Synuclein Misfolded Aggregates in Cerebrospinal Fluid","volume":"74","author":"Shahnawaz","year":"2017","journal-title":"JAMA Neurol."},{"issue":"2","key":"10.1007\/s13311-021-01161-z_bib51","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3988\/jcn.2019.15.2.135","article-title":"Alpha-Synuclein in Skin Nerve Fibers as a Biomarker for Alpha-Synucleinopathies","volume":"15","author":"Kim","year":"2019","journal-title":"J Clin Neurol."},{"issue":"Pt 3","key":"10.1007\/s13311-021-01161-z_bib52","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/brain\/awm322","article-title":"EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up","volume":"131","author":"Bonanni","year":"2008","journal-title":"Brain."},{"issue":"5","key":"10.1007\/s13311-021-01161-z_bib53","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s40520-020-01576-2","article-title":"Electroencephalogram in dementia with Lewy bodies: a systematic review","volume":"33","author":"Chatzikonstantinou","year":"2021","journal-title":"Aging Clin Exp Res."},{"issue":"Suppl 1","key":"10.1007\/s13311-021-01161-z_bib54","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/jnc.13390","article-title":"Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders","volume":"139","author":"Mollenhauer","year":"2016","journal-title":"J Neurochem."},{"issue":"1","key":"10.1007\/s13311-021-01161-z_bib55","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2217\/BMM.14.105","article-title":"The utility of alpha-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature","volume":"10","author":"Simonsen","year":"2016","journal-title":"Biomark Med."},{"issue":"1","key":"10.1007\/s13311-021-01161-z_bib56","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12916-018-1016-8","article-title":"Are dementia with Lewy bodies and Parkinson's disease dementia the same disease?","volume":"16","author":"Jellinger","year":"2018","journal-title":"BMC Med."},{"key":"10.1007\/s13311-021-01161-z_bib57","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.parkreldis.2019.12.005","article-title":"Effect of zonisamide on parkinsonism in patients with dementia with Lewy bodies: A phase 3 randomized clinical trial","volume":"76","author":"Murata","year":"2020","journal-title":"Parkinsonism Relat Disord."},{"issue":"4","key":"10.1007\/s13311-021-01161-z_bib58","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s40266-018-00636-7","article-title":"Pharmacological Management of Dementia with Lewy Bodies","volume":"36","author":"Hershey","year":"2019","journal-title":"Drugs Aging."},{"issue":"11","key":"10.1007\/s13311-021-01161-z_bib59","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1080\/13543784.2019.1681398","article-title":"Clinical drug development for dementia with Lewy bodies: past and present","volume":"28","author":"Lee","year":"2019","journal-title":"Expert Opin Investig Drugs."},{"issue":"2","key":"10.1007\/s13311-021-01161-z_bib60","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(19)30153-X","article-title":"New evidence on the management of Lewy body dementia","volume":"19","author":"Taylor","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1007\/s13311-021-01161-z_bib61","doi-asserted-by":"crossref","unstructured":"Sun C, Armstrong MJ. Treatment of Parkinson's Disease with Cognitive Impairment: Current Approaches and Future Directions. Behav Sci (Basel). 2021;11(4).","DOI":"10.3390\/bs11040054"},{"issue":"8","key":"10.1007\/s13311-021-01161-z_bib62","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/nm.3232","article-title":"The role of autophagy in neurodegenerative disease","volume":"19","author":"Nixon","year":"2013","journal-title":"Nat Med."},{"key":"10.1007\/s13311-021-01161-z_bib63","doi-asserted-by":"crossref","first-page":"259","DOI":"10.4172\/2155-9899.1000259","article-title":"Tyrosine Kinase Inhibition Regulates Early Systemic Immune Changes and Modulates the Neuroimmune Response in alpha-Synucleinopathy","volume":"5","author":"Hebron","year":"2014","journal-title":"J Clin Cell Immunol."},{"issue":"3","key":"10.1007\/s13311-021-01161-z_bib64","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1001\/jamaneurol.2020.4725","article-title":"Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial","volume":"78","author":"Simuni","year":"2021","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1007\/s13311-021-01161-z_bib65","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jamaneurol.2019.4200","article-title":"Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical Trial","volume":"77","author":"Pagan","year":"2020","journal-title":"JAMA Neurol."},{"issue":"5","key":"10.1007\/s13311-021-01161-z_bib66","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2174\/1567205011666140505100858","article-title":"A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943","volume":"11","author":"Schwam","year":"2014","journal-title":"Alzheimer's disease. Curr Alzheimer Res."},{"issue":"1","key":"10.1007\/s13311-021-01161-z_bib67","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13195-019-0467-2","article-title":"Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease","volume":"11","author":"Frolich","year":"2019","journal-title":"Alzheimers Res Ther."},{"issue":"1","key":"10.1007\/s13311-021-01161-z_bib68","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3233\/JAD-150277","article-title":"Selective Brain-Targeted Antagonism of p38 MAPKalpha Reduces Hippocampal IL-1beta Levels and Improves Morris Water Maze Performance in Aged Rats","volume":"48","author":"Alam","year":"2015","journal-title":"J Alzheimers Dis."},{"key":"10.1007\/s13311-021-01161-z_bib69","unstructured":"EIP Pharma Announces Positive Phase 2 Results for Neflamapimod in Mild-to-Moderate Dementia with Lewy bodies (DLB) [Internet]. EIP Pharma News. 2020 [Accessed 2021Oct24]. Available from: https:\/\/www.eippharma.com\/news\/eip-pharma-announces-positive-phase-2-results-for-neflamapimod-in-mild-to-moderate-dementia-with-lewy-bodies-dlb\/"},{"issue":"Pt 7","key":"10.1007\/s13311-021-01161-z_bib70","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1093\/brain\/awu119","article-title":"Convergence of pathology in dementia with Lewy bodies and Alzheimer's disease: a role for the novel interaction of alpha-synuclein and presenilin 1 in disease","volume":"137","author":"Winslow","year":"2014","journal-title":"Brain."},{"key":"10.1007\/s13311-021-01161-z_bib71","doi-asserted-by":"crossref","unstructured":"Armstrong MJ, Gamez N, Alliance S, Majid T, Taylor A, Kurasz AM, et al. Research priorities of caregivers and individuals with dementia with Lewy bodies: An interview study. PLoS One. 2020;15(10):e0239279.","DOI":"10.1371\/journal.pone.0239279"},{"key":"10.1007\/s13311-021-01161-z_bib72","unstructured":"Patel B, Irwin DJ, Kaufer D, Boeve BF, Taylor A, Armstrong MJ. Outcome Measures for Dementia with Lewy Body Clinical Trials: A Review. Alzheimer Dis Assoc Disord. In press."},{"issue":"5","key":"10.1007\/s13311-021-01161-z_bib73","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1093\/geront\/gnz179","article-title":"Patient-Reported Outcome Measures to Inform Care of People With Dementia-A Systematic Scoping Review","volume":"61","author":"Ayton","year":"2021","journal-title":"Gerontologist."},{"issue":"2","key":"10.1007\/s13311-021-01161-z_bib74","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/WAD.0b013e318065c4a9","article-title":"Patients with dementia with Lewy bodies have more impaired quality of life than patients with Alzheimer disease","volume":"21","author":"Bostrom","year":"2007","journal-title":"Alzheimer Dis Assoc Disord."},{"issue":"1","key":"10.1007\/s13311-021-01161-z_bib75","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13195-021-00792-w","article-title":"Characterization of symptoms and determinants of disease burden in dementia with Lewy bodies: DEvELOP design and baseline results","volume":"13","author":"van de Beek","year":"2021","journal-title":"Alzheimers Res Ther."},{"key":"10.1007\/s13311-021-01161-z_bib76","unstructured":"Aarsland DB, F.; Mollenhauer, B.; Biundo, R.; Svenningsson, P.; Lemstra, E.; McKeith, I. Multi-centre cohort studies in Lewy body dementia: Challenges in harmonizing different clinical and biomarker protocols. 2015."},{"key":"10.1007\/s13311-021-01161-z_bib77","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.dadm.2018.09.003","article-title":"Optimal cutoffs for the Montreal Cognitive Assessment vary by race and ethnicity","volume":"10","author":"Milani","year":"2018","journal-title":"Alzheimers Dement (Amst)."},{"issue":"3","key":"10.1007\/s13311-021-01161-z_bib78","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/WAD.0000000000000310","article-title":"Discriminative Ability of Montreal Cognitive Assessment Subtests and Items in Racial and Ethnic Minority Groups","volume":"33","author":"Milani","year":"2019","journal-title":"Alzheimer Dis Assoc Disord."},{"issue":"7","key":"10.1007\/s13311-021-01161-z_bib79","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1001\/jama.286.7.779-JMN0815-3-1","article-title":"Racial barriers may hamper diagnosis, care of patients with Alzheimer disease","volume":"286","author":"Stephenson","year":"2001","journal-title":"JAMA."},{"issue":"2","key":"10.1007\/s13311-021-01161-z_bib80","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/mds.27233","article-title":"Global scales for cognitive screening in Parkinson's disease: Critique and recommendations","volume":"33","author":"Skorvanek","year":"2018","journal-title":"Mov Disord."},{"issue":"10","key":"10.1007\/s13311-021-01161-z_bib81","doi-asserted-by":"crossref","first-page":"e1031","DOI":"10.1212\/WNL.0000000000012450","article-title":"Progression of Clinical Features in Lewy Body Dementia Can Be Detected Over 6 Months","volume":"97","author":"Matar","year":"2021","journal-title":"Neurology."},{"issue":"4","key":"10.1007\/s13311-021-01161-z_bib82","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00702-016-1517-6","article-title":"MMSE and MoCA in Parkinson's disease and dementia with Lewy bodies: a multicenter 1-year follow-up study","volume":"123","author":"Biundo","year":"2016","journal-title":"J Neural Transm (Vienna)."},{"issue":"10","key":"10.1007\/s13311-021-01161-z_bib83","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/gps.2823","article-title":"Assessment of cognitive fluctuation in dementia: a systematic review of the literature","volume":"27","author":"Lee","year":"2012","journal-title":"Int J Geriatr Psychiatry."},{"issue":"2","key":"10.1007\/s13311-021-01161-z_bib84","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1177\/1533317515603359","article-title":"Assessing Fluctuating Cognition in Dementia Diagnosis: Interrater Reliability of the Clinician Assessment of Fluctuation","volume":"31","author":"Van Dyk","year":"2016","journal-title":"Am J Alzheimers Dis Other Demen."},{"key":"10.1007\/s13311-021-01161-z_bib85","unstructured":"FDA. Early Alzheimer's disease: developing drugs for treatment guidance for industry. 2018."},{"key":"10.1007\/s13311-021-01161-z_bib86","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.trci.2018.11.004","article-title":"FDA position statement \u201cEarly Alzheimer's disease: Developing drugs for treatment, Guidance for Industry\u201d","volume":"5","author":"Sabbagh","year":"2019","journal-title":"Alzheimers Dement (N Y)."},{"issue":"1","key":"10.1007\/s13311-021-01161-z_bib87","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/brain\/awz311","article-title":"Cognitive fluctuations in Lewy body dementia: towards a pathophysiological framework","volume":"143","author":"Matar","year":"2020","journal-title":"Brain."},{"issue":"2","key":"10.1007\/s13311-021-01161-z_bib88","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1212\/WNL.62.2.181","article-title":"DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging","volume":"62","author":"Ferman","year":"2004","journal-title":"Neurology."},{"issue":"7","key":"10.1007\/s13311-021-01161-z_bib89","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1080\/13854046.2018.1517503","article-title":"Population Health Solutions for Assessing Cognitive Impairment in Geriatric Patients","volume":"32","author":"Perry","year":"2018","journal-title":"Clin Neuropsychol."},{"key":"10.1007\/s13311-021-01161-z_bib90","doi-asserted-by":"crossref","unstructured":"De Marchi F, Contaldi E, Magistrelli L, Cantello R, Comi C, Mazzini L. Telehealth in Neurodegenerative Diseases: Opportunities and Challenges for Patients and Physicians. Brain Sci. 2021;11(2).","DOI":"10.3390\/brainsci11020237"},{"issue":"1","key":"10.1007\/s13311-021-01161-z_bib91","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13195-021-00868-7","article-title":"Lewy Body Dementia Association's Industry Advisory Council: proceedings of the second annual meeting","volume":"13","author":"Goldman","year":"2021","journal-title":"Alzheimers Res Ther."},{"issue":"11","key":"10.1007\/s13311-021-01161-z_bib92","doi-asserted-by":"crossref","first-page":"E371","DOI":"10.1503\/cmaj.201938","article-title":"Virtual care for patients with Alzheimer disease and related dementias during the COVID-19 era and beyond","volume":"193","author":"Gosse","year":"2021","journal-title":"CMAJ."},{"issue":"10","key":"10.1007\/s13311-021-01161-z_bib93","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1017\/S1355617714000873","article-title":"Teleneuropsychology: evidence for video teleconference-based neuropsychological assessment","volume":"20","author":"Munro Cullum","year":"2014","journal-title":"J Int Neuropsychol Soc."},{"key":"10.1007\/s13311-021-01161-z_bib94","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association, American Psychiatric Association. DSM-5 Task Force. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Arlington, VA. Washington, D.C.: American Psychiatric Association; 2013. xliv, 947 pages p.","DOI":"10.1176\/appi.books.9780890425596"},{"issue":"5","key":"10.1007\/s13311-021-01161-z_bib95","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1212\/WNL.47.5.1113","article-title":"Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop","volume":"47","author":"McKeith","year":"1996","journal-title":"Neurology."}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01161-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-021-01161-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923001538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923001538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01161-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:36:50Z","timestamp":1761806210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923001538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":95,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1878747923001538"],"URL":"https:\/\/doi.org\/10.1007\/s13311-021-01161-z","relation":{},"ISSN":["1878-7479"],"issn-type":[{"type":"print","value":"1878-7479"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lewy Body Dementias: Controversies and Drug Development","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-021-01161-z","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}